Skip to main content

Table 6 A list of quality of life studies that covered measurement issues in breast cancer patients (1974–2007)

From: Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007

Author(s) [Ref.]


Main focus


Baum et al. [60]


The issue of measuring QOL in advanced breast cancer

Efforts are being made to find out ways to measure QOL in advanced breast cancer patients.

Sutherland et al. [61]


Ratings of the importance of QOL variables

Breast cancer patients give different weights to different QOL variables.

Gelber et al. [62]


Explaining about the QOL adjusted Time Without Symptom and Toxicity

Integration of two methods (QOL and symptom free duration) could provide a new tool.

Ganz et al. [63]


The influence of multiple variables on the relationship of age to QOL

The casement plot methodology should be employed for simultaneous evaluation of multiple variables.

Gelber et al. [64]


Description of survival estimates with applications to QOL evaluation (Quality adjusted Time Without Symptoms of disease and Toxicity of treatment)

Estimation showed that patients continued to benefit greatly from long-term-duration chemotherapy between 5 and 10 years following treatment.

Hyden et al. [65]


Pitfalls in collecting QOL data

Several recommendations were made: (a) build support for QOL assessment among the group's leadership, (b) involve physicians and oncology nurses in the study design, (c) identify a QOL liaison at each participating institution, and (d) aggressively monitor the quality and timeliness of data submission.

Fallowfield [66]


Measurement issues

Some recommendations for selecting well validated measures.

Gerard et al. [67]


Framing and labeling effects in measuring quality adjusted life years

A significant difference was found in the particular values of descriptions that were written in the third person that differed in terms of whether the word "cancer" was used.

Hurny et al. [68]


Timing of baseline QOL assessment

Timing is an important consideration in QOL assessment.

Fallowfield [69]


Discussion on some instruments used to measure QOL

Monitoring QOL in breast cancer should be a mandatory part of follow-up in clinical trials.

Hietanen [70]


Measurement and practical aspects of QOL assessment

Main factors affecting QOL in the treatment of breast cancer.

Bernhard et al. [71]


The International Breast Cancer Study Group (IBCSG) approach

Confirmation of the feasibility, validity and clinical relevance of quality of life assessment.

Bernhard et al. [72]


Factors affecting baseline QOL assessment

Cultural and biomedical factors are influencing baseline QOL data and should be considered when evaluating the impact of treatment.

Bernhard et al. [73]


Practical issues and factors associated with missing data

The factors most highly associated with missing data were institution and chemotherapy compliance.

Ganz et al. [74]


Compliance with QOL data collection

Educational level of a trial participants might contribute to it compliance.

Coates and Gebski [75]


Approaches to missing data

Missing data cannot be assumed to be similar to those available. Optimal assessment requires careful prospective attention to complete data collection.

Jansen et al. [76]


Response shift

Significant recalibration effects were observed.

Curran et al. [77]


Summary measures and statistics

Different techniques in analysis might result in different conclusions.

Perez et al. [78]


The application of a time trade-off utility measure

The utility measure and a QOL measure showed fair to moderate concordance.

Nagel et al. [79]


A cluster analytic approach to analyze quality of life data

QOL scores could identify clinically meaningful subgroups of patients.

Mosconi et al. [80]


A general introduction to the debate on the methodological issues involved in QOL evaluation

Open questions regarding the use of QOL measures in surgical, adjuvant therapy and metastatic studies.

Efficace et al. [81]


Evaluating reliability, validity and cultural relevance of QOL measures in clinical trials

Suggestions for selecting future measures for use in breast cancer population of patients.

Wilson et al. [82]


Comparing two QOL measures (the Rand 36-item and the Functional Living Index-Cancer)

Neither questionnaire can be replaced by each other in studies of QOL in breast cancer patients.

Carver et al. [83]


Assessment of demographic, medical and psychological variables on outcome

Different aspects of QOL at long-term follow-up had different antecedents.

Perry et al. [84]


Benefits, acceptability and utilization of QOL assessment in women with breast cancer

Summarized the benefits, challenges, and barriers of QOL measurement for female breast cancer patients.